{"id":"pembrolizumab-monotherapy","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Fatigue"},{"rate":"15-25","effect":"Decreased appetite"},{"rate":"10-20","effect":"Nausea"},{"rate":"10-20","effect":"Diarrhea"},{"rate":"10-20","effect":"Rash"},{"rate":"3-5","effect":"Immune-mediated pneumonitis"},{"rate":"2-4","effect":"Immune-mediated colitis"},{"rate":"1-3","effect":"Immune-mediated hepatitis"},{"rate":"1-5","effect":"Immune-mediated endocrinopathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pembrolizumab binds to programmed death receptor-1 (PD-1) on T lymphocytes, preventing interaction with its ligands PD-L1 and PD-L2 on tumor cells and immune cells. This blockade releases the 'brakes' on T-cell-mediated immunity, restoring anti-tumor immune responses. The drug is used as monotherapy in various cancers where PD-L1 expression or tumor microenvironment characteristics predict responsiveness.","oneSentence":"Pembrolizumab is a monoclonal antibody that blocks PD-1 on T cells, allowing the immune system to recognize and attack cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:48:27.010Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Melanoma (unresectable or metastatic)"},{"name":"Non-small cell lung cancer (metastatic, PD-L1 positive)"},{"name":"Head and neck squamous cell carcinoma (recurrent or metastatic)"},{"name":"Hodgkin lymphoma (relapsed or refractory)"},{"name":"Urothelial carcinoma (locally advanced or metastatic)"},{"name":"Gastric or gastroesophageal junction adenocarcinoma (PD-L1 positive)"}]},"trialDetails":[{"nctId":"NCT06225596","phase":"PHASE2, PHASE3","title":"Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)","status":"RECRUITING","sponsor":"BicycleTx Limited","startDate":"2024-01-24","conditions":"Metastatic Urothelial Cancer","enrollment":956},{"nctId":"NCT06841354","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-16","conditions":"Triple Negative Breast Neoplasms","enrollment":1000},{"nctId":"NCT07247110","phase":"PHASE1","title":"A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-16","conditions":"Malignant Neoplasm","enrollment":250},{"nctId":"NCT06295809","phase":"PHASE2, PHASE3","title":"A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-18","conditions":"Carcinoma, Squamous Cell, Skin Neoplasms","enrollment":46},{"nctId":"NCT06422143","phase":"PHASE3","title":"Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-10","conditions":"Non-small Cell Lung Cancer, NSCLC","enrollment":851},{"nctId":"NCT05763004","phase":"PHASE1","title":"A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunOs Therapeutics AG","startDate":"2023-03-15","conditions":"Solid Tumor, Adult","enrollment":140},{"nctId":"NCT07361510","phase":"PHASE3","title":"A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-03-12","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":750},{"nctId":"NCT06627647","phase":"PHASE3","title":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-11-27","conditions":"Non-squamous Non-small Cell Lung Cancer","enrollment":878},{"nctId":"NCT06312137","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-03","conditions":"Non Small Cell Lung Cancer","enrollment":780},{"nctId":"NCT04234113","phase":"PHASE1","title":"Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors","status":"TERMINATED","sponsor":"SOTIO Biotech AG","startDate":"2019-06-13","conditions":"Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer","enrollment":115},{"nctId":"NCT06525220","phase":"PHASE3","title":"A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)","status":"RECRUITING","sponsor":"Merus B.V.","startDate":"2024-09-25","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":500},{"nctId":"NCT06170788","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-15","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":614},{"nctId":"NCT04670679","phase":"PHASE1","title":"A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Erasca, Inc.","startDate":"2020-12-15","conditions":"Advanced or Metastatic Solid Tumors","enrollment":90},{"nctId":"NCT06343402","phase":"PHASE1","title":"Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)","startDate":"2024-05-22","conditions":"Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC","enrollment":350},{"nctId":"NCT04534205","phase":"PHASE2, PHASE3","title":"A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2021-01-07","conditions":"Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer","enrollment":350},{"nctId":"NCT03899155","phase":"PHASE2","title":"Pan Tumor Rollover Study","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2019-08-09","conditions":"Cancer","enrollment":1500},{"nctId":"NCT03288545","phase":"PHASE1, PHASE2","title":"A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2017-10-11","conditions":"Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms","enrollment":348},{"nctId":"NCT06462794","phase":"PHASE1","title":"First In Human Study of CX-801 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"CytomX Therapeutics","startDate":"2024-08-28","conditions":"Solid Tumor, Adult","enrollment":121},{"nctId":"NCT06917079","phase":"PHASE1","title":"BBO-11818 in Adult Subjects With KRAS Mutant Cancer","status":"RECRUITING","sponsor":"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)","startDate":"2025-03-31","conditions":"Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":387},{"nctId":"NCT05614739","phase":"PHASE1","title":"FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2023-01-12","conditions":"Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms","enrollment":535},{"nctId":"NCT07218003","phase":"PHASE1","title":"A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4","status":"ENROLLING_BY_INVITATION","sponsor":"Rondo Therapeutics","startDate":"2025-11-17","conditions":"Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer","enrollment":149},{"nctId":"NCT05537740","phase":"PHASE1","title":"A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2022-10-11","conditions":"Advanced Solid Tumors","enrollment":129},{"nctId":"NCT07182591","phase":"PHASE1","title":"A Study of DS5361b in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-10-02","conditions":"Advanced Solid Tumor","enrollment":192},{"nctId":"NCT06952504","phase":"PHASE3","title":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-22","conditions":"Endometrial Cancer","enrollment":1123},{"nctId":"NCT05923190","phase":"PHASE2","title":"Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2023-06-14","conditions":"Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma","enrollment":60},{"nctId":"NCT04938817","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-08-19","conditions":"Small Cell Lung Carcinoma","enrollment":110},{"nctId":"NCT07195695","phase":"PHASE3","title":"Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2026-01-16","conditions":"Non-small Cell Lung Cancer","enrollment":400},{"nctId":"NCT06108479","phase":"PHASE1","title":"Study of DF6215 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Dragonfly Therapeutics","startDate":"2023-11-28","conditions":"Solid Tumor, Adult, Solid Tumor Cancer","enrollment":35},{"nctId":"NCT06806852","phase":"PHASE1","title":"A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2025-05-14","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":90},{"nctId":"NCT05098132","phase":"PHASE1, PHASE2","title":"Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers","status":"RECRUITING","sponsor":"Synthekine","startDate":"2022-01-25","conditions":"Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC","enrollment":364},{"nctId":"NCT04613596","phase":"PHASE2, PHASE3","title":"Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7","status":"RECRUITING","sponsor":"Mirati Therapeutics Inc.","startDate":"2020-12-02","conditions":"Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer","enrollment":806},{"nctId":"NCT05101070","phase":"PHASE1, PHASE2","title":"S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Shionogi","startDate":"2022-05-30","conditions":"Solid Tumors","enrollment":282},{"nctId":"NCT04958239","phase":"PHASE1","title":"A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2021-10-18","conditions":"Neoplasms","enrollment":151},{"nctId":"NCT07223047","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-11-25","conditions":"Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)","enrollment":252},{"nctId":"NCT07403136","phase":"PHASE2","title":"Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2026-02-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":52},{"nctId":"NCT06960395","phase":"PHASE1","title":"Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Vir Biotechnology, Inc.","startDate":"2025-07-22","conditions":"Solid Tumor Malignancies, EGFR Positive Solid Tumors, EGFR","enrollment":450},{"nctId":"NCT06894771","phase":"PHASE1","title":"A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-23","conditions":"Malignant Neoplasm","enrollment":5},{"nctId":"NCT07287995","phase":"PHASE1, PHASE2","title":"A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2026-02-05","conditions":"Locally Advanced or Metastatic Malignant Solid Tumors","enrollment":428},{"nctId":"NCT04389632","phase":"PHASE1","title":"A Study of Sigvotatug Vedotin in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2020-06-08","conditions":"Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms","enrollment":1006},{"nctId":"NCT04083599","phase":"PHASE1, PHASE2","title":"GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2019-09-17","conditions":"Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)","enrollment":350},{"nctId":"NCT06357533","phase":"PHASE3","title":"Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-04-11","conditions":"Non-Small Cell Lung Cancer","enrollment":675},{"nctId":"NCT05853367","phase":"PHASE1","title":"Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-07-06","conditions":"Metastatic Solid Tumors, Advanced Solid Tumors","enrollment":178},{"nctId":"NCT06264180","phase":"PHASE3","title":"VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]","status":"RECRUITING","sponsor":"Replimune Inc.","startDate":"2024-07-11","conditions":"Advanced Melanoma","enrollment":400},{"nctId":"NCT06385080","phase":"PHASE1, PHASE2","title":"A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-04-22","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":287},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT06607185","phase":"PHASE1","title":"A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-10-21","conditions":"Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer","enrollment":750},{"nctId":"NCT03786081","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2019-02-27","conditions":"Cervical Cancer","enrollment":214},{"nctId":"NCT05410145","phase":"PHASE1, PHASE2","title":"A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation","status":"RECRUITING","sponsor":"D3 Bio (Wuxi) Co., Ltd","startDate":"2022-08-03","conditions":"KRAS P.G12C","enrollment":442},{"nctId":"NCT04585750","phase":"PHASE1, PHASE2","title":"The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","status":"RECRUITING","sponsor":"PMV Pharmaceuticals, Inc","startDate":"2020-10-29","conditions":"Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer","enrollment":300},{"nctId":"NCT06758401","phase":"PHASE3","title":"This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-07-23","conditions":"Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)","enrollment":714},{"nctId":"NCT06234397","phase":"PHASE1","title":"Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2023-12-28","conditions":"Advanced or Metastatic Solid Tumors","enrollment":245},{"nctId":"NCT03142334","phase":"PHASE3","title":"Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-06-09","conditions":"Renal Cell Carcinoma","enrollment":994},{"nctId":"NCT05689671","phase":"PHASE4","title":"Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nikolaj Frost MD","startDate":"2023-12-06","conditions":"Non-Small Cell Lung Cancer Metastatic","enrollment":136},{"nctId":"NCT03221426","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-09","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":1007},{"nctId":"NCT05499390","phase":"PHASE3","title":"AK112 in Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2022-11-09","conditions":"Advanced Non-small-cell Lung Cancer","enrollment":398},{"nctId":"NCT07020221","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors","status":"RECRUITING","sponsor":"Verastem, Inc.","startDate":"2025-06-24","conditions":"Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer","enrollment":295},{"nctId":"NCT06488482","phase":"PHASE3","title":"Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2024-12-19","conditions":"High-risk Melanoma","enrollment":1792},{"nctId":"NCT04736173","phase":"PHASE2","title":"Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arcus Biosciences, Inc.","startDate":"2021-02-08","conditions":"Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer","enrollment":169},{"nctId":"NCT04262466","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immunocore Ltd","startDate":"2020-02-25","conditions":"Select Advanced Solid Tumors","enrollment":410},{"nctId":"NCT05346484","phase":"PHASE1","title":"A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors","status":"TERMINATED","sponsor":"Imugene Limited","startDate":"2022-05-17","conditions":"Solid Tumor, Solid Carcinoma, Solid Tumor, Adult","enrollment":66},{"nctId":"NCT07227168","phase":"PHASE1","title":"A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer","status":"RECRUITING","sponsor":"Sutro Biopharma, Inc.","startDate":"2025-11-07","conditions":"Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer","enrollment":200},{"nctId":"NCT05721755","phase":"PHASE3","title":"Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-06-08","conditions":"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma","enrollment":290},{"nctId":"NCT05463848","phase":"PHASE2","title":"Surgical Pembro +/- Olaparib w TMZ for rGBM","status":"RECRUITING","sponsor":"L. Nicolas Gonzalez Castro, MD, PhD","startDate":"2022-10-21","conditions":"Glioblastoma, Recurrent Glioblastoma","enrollment":78},{"nctId":"NCT05579366","phase":"PHASE1, PHASE2","title":"Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)","status":"RECRUITING","sponsor":"Genmab","startDate":"2022-12-07","conditions":"High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma","enrollment":764},{"nctId":"NCT06984328","phase":"PHASE2","title":"Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2025-07-25","conditions":"Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), Metastatic Cutaneous Melanoma (Stage IV)","enrollment":1},{"nctId":"NCT06057038","phase":"PHASE1","title":"A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2023-11-24","conditions":"Malignant Solid Tumor","enrollment":42},{"nctId":"NCT06994806","phase":"PHASE1","title":"A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies","status":"RECRUITING","sponsor":"Kumquat Biosciences Inc.","startDate":"2025-06-24","conditions":"Solid Tumor Malignancies","enrollment":84},{"nctId":"NCT04855435","phase":"PHASE1","title":"Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours","status":"RECRUITING","sponsor":"MonTa Biosciences ApS","startDate":"2021-04-12","conditions":"Advanced Solid Tumor, Uveal Melanoma, Metastatic, Cutaneous Melanoma","enrollment":106},{"nctId":"NCT07026474","phase":"PHASE3","title":"Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC","status":"RECRUITING","sponsor":"Universität des Saarlandes","startDate":"2025-10-30","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":214},{"nctId":"NCT05382559","phase":"PHASE1","title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2022-06-08","conditions":"Solid Tumor","enrollment":681},{"nctId":"NCT07262619","phase":"PHASE1, PHASE2","title":"EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors","status":"RECRUITING","sponsor":"Eikon Therapeutics","startDate":"2026-01-22","conditions":"Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer","enrollment":160},{"nctId":"NCT06868277","phase":"PHASE3","title":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-04-10","conditions":"Carcinoma, Non-Small Cell Lung","enrollment":830},{"nctId":"NCT05083481","phase":"PHASE1, PHASE2","title":"A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-10-19","conditions":"Advanced Solid Tumors","enrollment":366},{"nctId":"NCT06745882","phase":"PHASE2","title":"Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2025-06-13","conditions":"Non-small Cell Lung Cancer","enrollment":318},{"nctId":"NCT06447662","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-06-27","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":330},{"nctId":"NCT05549297","phase":"PHASE3","title":"Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)","status":"RECRUITING","sponsor":"Immunocore Ltd","startDate":"2022-12-19","conditions":"Advanced Melanoma","enrollment":540},{"nctId":"NCT05081609","phase":"PHASE1, PHASE2","title":"A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ascendis Pharma Oncology Division A/S","startDate":"2022-01-11","conditions":"Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":320},{"nctId":"NCT05753722","phase":"PHASE1","title":"A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies","status":"RECRUITING","sponsor":"Incendia Therapeutics","startDate":"2023-03-03","conditions":"Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer, NSCLC","enrollment":270},{"nctId":"NCT04379596","phase":"PHASE2","title":"Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2020-06-03","conditions":"Gastric Cancer","enrollment":450},{"nctId":"NCT05208762","phase":"PHASE1","title":"A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2022-10-25","conditions":"Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma","enrollment":714},{"nctId":"NCT04738487","phase":"PHASE3","title":"Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-04-07","conditions":"Lung Neoplasms, Non-Small-Cell Lung Carcinoma","enrollment":1264},{"nctId":"NCT07422779","phase":"NA","title":"Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia","status":"RECRUITING","sponsor":"Institute of Oncology Ljubljana","startDate":"2022-03-01","conditions":"Metastatic Melanoma, Skin Cancer","enrollment":100},{"nctId":"NCT05239624","phase":"PHASE2","title":"Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-06-02","conditions":"Urothelial Carcinoma","enrollment":23},{"nctId":"NCT04485013","phase":"PHASE1","title":"TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers","status":"RECRUITING","sponsor":"Tizona Therapeutics, Inc","startDate":"2020-07-14","conditions":"Cancer","enrollment":240},{"nctId":"NCT07166601","phase":"PHASE1","title":"M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors","status":"RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2025-10-10","conditions":"Advanced Solid Tumor","enrollment":77},{"nctId":"NCT06600321","phase":"PHASE1","title":"A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Alnylam Pharmaceuticals","startDate":"2024-12-30","conditions":"Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma","enrollment":158},{"nctId":"NCT06004245","phase":"PHASE1","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Vividion Therapeutics, Inc.","startDate":"2024-01-25","conditions":"Advanced Solid Tumors","enrollment":295},{"nctId":"NCT04041310","phase":"PHASE1, PHASE2","title":"Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nouscom SRL","startDate":"2019-10-21","conditions":"Solid Tumor, Adult","enrollment":115},{"nctId":"NCT05365581","phase":"PHASE1","title":"A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2022-06-07","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma","enrollment":398},{"nctId":"NCT05493566","phase":"EARLY_PHASE1","title":"Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Emory University","startDate":"2022-11-01","conditions":"Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8","enrollment":15},{"nctId":"NCT05067283","phase":"PHASE1","title":"A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-12-17","conditions":"Advanced Solid Tumors","enrollment":830},{"nctId":"NCT07094113","phase":"PHASE1","title":"AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Amgen","startDate":"2025-07-31","conditions":"KRAS Altered Advanced or Metastatic Solid Tumors","enrollment":434},{"nctId":"NCT05993234","phase":"","title":"A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)","status":"RECRUITING","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2023-12-05","conditions":"HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma","enrollment":257},{"nctId":"NCT06557889","phase":"PHASE2","title":"Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas","status":"RECRUITING","sponsor":"Institut Claudius Regaud","startDate":"2024-10-21","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":86},{"nctId":"NCT03917381","phase":"PHASE1, PHASE2","title":"GEN1046 Safety Trial in Patients With Malignant Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2019-05-14","conditions":"Solid Tumors","enrollment":429},{"nctId":"NCT07360743","phase":"PHASE2","title":"Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-04","conditions":"Non Small Cell Lung Cancer (Squamous or Non Squamous)","enrollment":275},{"nctId":"NCT05787587","phase":"PHASE1","title":"A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"IDEAYA Biosciences","startDate":"2023-04-18","conditions":"Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer","enrollment":216},{"nctId":"NCT04044859","phase":"PHASE1","title":"ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"USWM CT, LLC","startDate":"2019-08-20","conditions":"Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ)","enrollment":120},{"nctId":"NCT05479812","phase":"PHASE1","title":"Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Werewolf Therapeutics, Inc.","startDate":"2022-05-20","conditions":"Metastatic Solid Tumor, Advanced Solid Tumor","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":636,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["KEYTRUDA","Keytruda"],"phase":"phase_3","status":"active","brandName":"Pembrolizumab Monotherapy","genericName":"Pembrolizumab Monotherapy","companyName":"PDS Biotechnology Corp.","companyId":"pds-biotechnology-corp","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pembrolizumab is a monoclonal antibody that blocks PD-1 on T cells, allowing the immune system to recognize and attack cancer cells. Used for Melanoma (unresectable or metastatic), Non-small cell lung cancer (metastatic, PD-L1 positive), Head and neck squamous cell carcinoma (recurrent or metastatic).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}